18 closest matches · ranked by relevance
Typhoid Fever
Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 85; 100; 89 percentage of subjects
Typhoid
Primary: Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions. — 0; 0; 0; 0 Participants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 100; 100; 11 percentage of subjects
Cognitive Side Effects of Cancer Therapy · Depression · Recurrent Breast Carcinoma
Primary: AUC Change in Level of IL-6 — 5.23; 10.17 ug*hour/ml
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 23; 16 participants
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 18; 19; 22; 16 participants
Salmonella Infections · Typhoid Fever · Bacterial Infections
Primary: Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine — 173; 6; 5 Participants
Cancer of the Liver · Liver Cancer · Hepatoma
Primary: Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium — 0; 0; 0; 0 Participants
Typhoid Fever
Primary: Number of Infants With Adverse Reactions After Vaccination — 22; 24; 17; 7 participants
Enteric Fever
Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants
Salmonella Infections
Primary: Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration — 1; 0; 0; 0 Participants
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
Diarrhea
Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants
Shigellosis
Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants
Shigella
Primary: Number of Participants With Moderate-Severe Shigellosis Illness, With Challenge — 14; 17 Participants
Infection
Primary: Percentage of Participants With Clinical and Microbiological Cure: All Participants — 33.8 percentage of participants
Complicated Skin and Skin Structure Infections · Complicated Intra-abdominal Infections
Primary: Number of Participants With Spontaneous Adverse Events — 17 Participants